6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity
- Aradigm has a unique pipeline in development targeting undertreated respiratory diseases.
- There is almost no coverage to be found on Aradigm. Wall Street has yet to discover this company, which is rare for a Phase III biotech stock.
- Aradigm’s excellent financials, partnership with a major pharmaceutical company and stable share price significantly reduce downside risk.
- Aradigm looks severely undervalued. This reduces downside risk too, and amplifies upside potential.